You may have access to the free features available through My Research. You can save searches, save documents, create alerts and more. Please log in through your library or institution to check if you have access.
If you log in through your library or institution you might have access to this article in multiple languages.
Styles include MLA, APA, Chicago and many more. This feature may be available for free if you log in through your library or institution.
You may have access to it for free by logging in through your library or institution.
You may have access to different export options including Google Drive and Microsoft OneDrive and citation management tools like RefWorks and EasyBib. Try logging in through your library or institution to get access to these tools.
You might have access to the full article...
Try and log in through your institution to see if they have access to the full text.
Celltech, the UK's biggest biotech, is being taken over for around pounds 1.5 billion by UCB, the Belgian drug and chemicals group.
The board has approved the offer, worth 550p a share in cash (compared with 360p back in January when we recommended a modest purchase) and chairman Dr Peter Fellner told shareholders at their annual meeting that big institutional shareholders had been "supportive". It...
